CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOACaptura de pantalla 2022 09 14 a las 10.27.10    

Group of cellular signaling networks in cancer (onco-resecel)

Research summary:

Breast cancer is a disease of high prevalence with around 25,000 new diagnoses in Spain each year. Its incidence is much higher in the developed world, suggesting that the western lifestyle with unhealthy dietary habits (excessive caloric intake, overweight, obesity) and chronic stress states (adrenergic overstimulation) may influence the onset and progression of this disease.

The histopathological variety and molecular heterogeneity of breast tumors (luminal subtypes, triple negative, ERBB2), together with genomic instability and intra-tumoral cellular diversity, are factors that make difficult to achieve efficient treatments. In breast cancer, the main altered proteins responsible for genomic instability and heterogeneity are ATM kinase, Brca1 ligase and the tumor suppressor transcription factor p53 together with its negative regulator Mdm2 ligase. Although in ~ 80% of ductal breast carcinomas p53 is restrained by the activation/amplification of Mdm2 or by the deactivation of positive regulators such as ATM, therapies based on these targets are not yet satisfactory.

Image

Fig 1. The Mdm2/GRK2/HDAC6 axis plays a key role in breast cancer progression. The interdependent activation of these signaling hubs promotes breast tumorogenesis through the stimulation of pro-tumoral angiogenesis, cellular proliferation, invasion and metastasis.

However, the identification of molecular dependencies in certain types of breast cancer has improved the treatment of patients with ERBB2(Her2) + or luminal tumors by using drugs directed against the HER2 tyrosine kinase receptor or the estrogen receptor (ER). However, in “triple negative” tumors (TNBCs) (negative for the steroid receptor (ER), progesterone (PR) and ERBB2 receptor) there are no clearly identified dependencies, and the treatments are not sufficiently effective. Another important problem is the emergence of resistance in luminal, Her2 and triple negative breast cancers, in parallel to the heterogeneity due to genomic instability and tumor metabolic reprogramming.

The objective of our group is to identify, as potential multifunctional therapeutic targets, signaling nodes that cooperate with oncogenes in the acquisition of tumor capacities (angiogenesis, proliferation, invasion or metastasis) or that block the activity of tumor suppressors, being able to alter the cellular homeostasis.

Results of our laboratory suggest that intertwined alterations of the serine-threonine kinase GRK2 and the Mdm2 ligase are key for cell-autonomous malignant transformation, as well as in the interplay of the transformed cell with the tumor micro-environment and the systemic condition of the patient. Our results indicate that these proteins modulate each other differently in normal epithelial cells and in tumor cells, responding in different ways to signals that stimulate adrenergic receptors and other G-protein coupled receptors (GPCR) or growth factor tyrosine kinase receptors (RTK).

Image

Fig. 2. Animal models to study the role of the GRK2 / Mdm2 axis in the influence of various environmental stressors on tumor progression.

In this context, our research aims to characterize the role of these nodes (GRK2 and Mdm2), as the relevant proteins phosphorylated and ubiquitinated by them, in a) diverse cellular processes such as cell cycle control and cell division, differentiation, energy metabolism or senescence, which are key in maintaining a normal cell behavior; b) in the consequences of hormonal (adrenergic, estrogenic) and metabolic stress on genomic stability; and c) in pro-tumoral stroma remodeling by analyzing the pathological angiogenesis and fibrosis that facilitate tumor growth and dissemination.

Image

Fig. 3. Concurrent upregulation of GRK2 and Mdm2 is a feature of tumor breast epithelial cells, particularly in the hormone receptor-positive luminal subtype, which confers cellular chemoresistance.

Image


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Arroba GallegoJavier320911964652Estudiante TFM
García MateosDafne320/3044652/4656dafne.garcia(at)cbm.csic.esTitulado Sup.de Actividades Técn. y Profes. GP1
González MuñozTeresa3204652Investigador Indef. GP1
Moyano JimenoClara 3204652cmoyano(at)cbm.csic.esTitulado Sup.Inv.y Laboratorio
Nogués VeraLaura3204640lnogues(at)cbm.csic.esProfesor Ayudante Doctor Universidad
Penela MárquezPetronila3204640ppenela(at)cbm.csic.esProfesor Titular Universidad, GA
Rodríguez BlancoClara3204652Estudiante TFG
Vázquez de OroEstefanía3204652evazquez(at)cbm.csic.esTco. de Investigación y Laboratorio

Relevant publications:

  • P Penela; J Inserte; P Ramos; D García-Dorado; F Mayor Jr. Degradation of GRK2 and AKT is an early and detrimental event in ischemia/reperfusion. EbioMedicine (2019) in press
  • P Penela; C Ribas; F Sánchez-Madrid; F Mayor Jr. G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub. Cellular and Molecular Life Sciences (2019) doi: 10.1007/s00018-019-03274-3
  • D Aluja; J Inserte J; P Penela; P Ramos; C Ribas; MA Iñiguez; F Mayor Jr; D Garcia-Dorado. Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2. Basic Research in Cardiology (2019) 114: 21 (1-14)
  • L Nogués; J Palacios-García; C Reglero; V Rivas; M Neves; C Ribas; P Penela; F Mayor. G protein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression: GPCR regulators and signaling hubs. Seminars in Cancer Biology. (2018) S1044-579X(17)
  • L. Nogués, C. Reglero, V. Rivas, M. Neves, P. Penela and F. Mayor Jr. G protein-coupled receptor kinase 2 (GRK2) as a potential modulator of the hallmarks of cancer. Mol. Pharmacol. (2017) 91: 220-228
  • L. Nogués, C. Reglero, V. Rivas, A. Salcedo, V. Lafarga, M. Neves, P. Ramos , M. Mendiola, A. Berjón, K. Stamatakis, X. Z. Zhou, K. P. Lu, D.Hardisson, F. Mayor, jr., and P.Penela. G protein-coupled receptor kinase 2 (GRK2) promotes breast tumorigenesis through a novel HDAC6-Pin1 axis. EBioMedicine (2016) 13: 132-145
  • P. Penela. Ubiquitination and Protein Turnover of G Protein coupled Receptor Kinases in GPCR Signaling and Cellular Regulation. Progress in Molecular Biology and Translation Science (2016) 141: 85-140
  • V. Rivas, L. Nogués, C. Reglero, F. Mayor .Jr. and P. Penela. Role of G protein-coupled receptor kinase 2 in tumoural angiogenesis Mol. Cell. Oncol. (2014) e969166-1-11
  • Fernández-Arenas E, Calleja E, Martínez-Martín N, Gharbi SI, Navajas R, García-Medel N, Penela P, Alcamí A, Mayor F Jr, Albar JP, Alarcón B.β-Arrestin-1 mediates the TCR-triggered re-routing of distal receptors to the immunological synapse by a PKC-mediated mechanism. EMBO J.(2014) 33: 559-577
  • P. Penela, L. Nogués, and F. Mayor Jr. Roles of GRKs in cell migration. Curr. Opin. Cell Biol. (2014) 27: 10-17
  • V. Rivas , R. Carmona ., R. Muñoz-Chápuli, M. Mendiola, L. Nogués, C. Reglero, M. Miguel-Martín, R. García-Escudero, G. W Dorn II, D. Hardisson, F. Mayor, jr. and P. Penela. Developmental and tumoural vascularization is regulated by G-protein-coupled receptor kinase 2. J. Clin. Invest (2013) 123: 4714-4730

Doctoral theses:

  • Verónica Rivas Guerrero (2018) “Caracterización del papel funcional de GRK2 en la fisiología del endotelio y en los procesos vasculares de angiogénesis y vasculogénesis”
  • Clara Reglero Gomez (2017) “Regulation of GRK2 by Mdm2 and the APC/C complex: a way to fine-tune dynamics and faithful progression of the cell cycle”
  • Laura Nogués Vera (2014) “GRK2 as a new onco-modulator of breast tumoural transformation through the regulation of the p53/MDM2 axis”

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

COOKIES POLICY

What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers:

fondosocialeuropeo-300px.png
Ministerio-de-Ciencia-e-Innovacin-600px.png
Comunidad-de-Madrid-600Bpx.png
agenda20-30-600px.png
fundacion-areces600px0710.png
LOGO_ERC.jpg
hrexcellence.jpg
worldwidecancerresearch-600px0710.png
aecc-600tpx.png
bbva-fund-400.png
Niemann-Pick-400px.png
wilderfund-400px.png
AliciaKoplowitz-400px.png
la-caixa-fund-600px.png
inocente-inocente-600px.png
cure-alzheimers-fund-600px.png
citrin-foundation.png
tatiana-fund02-600bpx1.png
campus-excelencia-600x400px.png
fundacion-uno-entre-cien-mil-v02.png